Basic Information
| LncRNA/CircRNA Name | EGFR-AS1 |
| Synonyms | NA |
| Region | GRCh38_7:55179750-55188934 |
| Ensemble | ENSG00000224057 |
| Refseq | NR_047551 |
| Regulatory Mechanism | Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | cisplatin and gemcitabine | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Information of Cancer
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, Other |
| Sample | plasma, NLCLC tissues and cell lines (A549, NCI-H460, NCI-H1299 and NCI-H358) |
| Expression Pattern | up-regulated |
| Function Description | EGFR-AS1 was abnormally upregulated in NSCLC tissues compared with adjacent normal lung tissues. Furthermore, patients with NSCLC with increased expression of EGFR-AS1 had a poor prognosis. EGFR-AS1 knockdown significantly inhibited NSCLC malignancy in vitro, including cell proliferation and chemoresistance. Furthermore, the expression levels of EGFR-AS1 were increased in plasma samples from patients with cisplatin-based chemotherapy resistance. Bioinformatics analysis and a luciferase reporter assay confirmed that EGFR-AS1 mediated cell proliferation and chemoresistance through directly binding to microRNA-223. Therefore, EGFR-AS1 overexpression-induced chemoresistance can contribute to poor prognosis in NSCLC. |
| Pubmed ID | 30431074 |
| Year | 2019 |
| Title | Overexpression of lncRNA EGFR-AS1 Is Associated With a Poor Prognosis and Promotes Chemotherapy Resistance in Non-small Cell Lung Cancer |
External Links
| Links for EGFR-AS1 | GenBank HGNC Noncode |
| Links for non small cell lung cancer | Omim Cosmic |